Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

129.43 +1.01 (+0.79%)
Streaming Delayed Price Updated: 2:36 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
1 High-Yield Vanguard Dividend Fund to Buy Hand Over Fist
This international dividend powerhouse quietly delivered 26.6% returns this year -- more than doubling the S&P 500 while paying triple the income. 
Via The Motley Fool
Topics ETFs Stocks
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology. 
Via The Motley Fool
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms
Palantir is strengthening its role in the US industry through partnerships with Lear and Lumen and will showcase customer success stories at its AIPCon 8 event in September 2025. 
Via Benzinga
Topics Artificial Intelligence
Palantir Hosts Eighth AIPCon. Stays Above 50-Day Line. Is PLTR Stock A Buy?
Palantir stock bulls tout the software maker's AI strategy and strong U.S. government business amid a lofty valuation for PLTR stock. 
Via Investor's Business Daily
Topics Artificial Intelligence ETFs Government
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’
Via Stocktwits
How Is The Market Feeling About Novartis?
 
Via Benzinga
Why Did Bollinger Innovations Stock Plunge 18% Today?
The company stated that it has eliminated third-party manufacturing, specifically with Roush Industries, and has instead consolidated the B4 production line from Roush Industries to the company-owned... 
Via Stocktwits
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug. 
Via Investor's Business Daily
Gateway to Growth: Innovation and Opportunity at the 8th CIIE
Via Press Release Distribution Service
Topics Economy
Gateway to Growth: Innovation and Opportunity at the 8th CIIE
Via Get News
Topics Economy
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook
Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting. 
Via Benzinga
P/E Ratio Insights for Novartis
 
Via Benzinga
Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns
Via Stocktwits
Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates. 
Via Benzinga
Novartis AG-Sponsored ADR (NYSE:NVS) – A Top Dividend Stock with Strong Yield and Financial Stability
Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing. 
Via Chartmill
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
These companies have successfully navigated similar obstacles before. 
Via The Motley Fool
Topics Intellectual Property
2 Dividend Stocks to Buy and Hold
These stocks look like they can weather almost any storm. 
Via The Motley Fool
Topics Artificial Intelligence Cannabis Government
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Emerges as a Top Pick for Value Investors with Strong Fundamentals and Attractive Valuation
Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation. 
Via Chartmill
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease. 
Via Benzinga
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial. 
Via Benzinga
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
Truist, however, kept a ‘Buy’ rating on the shares. 
Via Stocktwits
Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease. 
Via Stocktwits
Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings. 
Via Benzinga
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
PTCT Earnings Beat but Sales Drop 4%
Via The Motley Fool
Topics Earnings
Monte Rosa (GLUE) Q2 Revenue Jumps 394%
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.